Celldex Therapeutics, Inc.: financial reference

Context from the filing

For 2023–2025, Celldex reports equal basic and diluted net loss per common share. Its policy excludes potential common shares in loss periods because their effect would be anti-dilutive. Basic weighted-average shares exclude issued restricted stock that has not vested. The statement presents share counts in thousands; its inline tags encode that scale, and these pages show the reported counts in shares. Per-share amounts are not scaled by thousands. Basic and diluted measures retain distinct definitions, and their matching denominators should not be added. Read the source filing.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Filings

• 10-Q filed 2026-08-06
• 10-Q filed 2026-05-07
• 10-K filed 2026-02-25
• 10-Q filed 2025-11-10
• 10-Q filed 2025-08-07

62 Celldex Therapeutics filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.

Inspect the source

Entity

Celldex Therapeutics, Inc. / CIK 0000744218

Captured

2026-09-19 15:01 UTC

SEC response SHA-256

a253f724b1319f3eeec0fb678b43576159c8fa993fc97e4268adfafa9963e2f2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000744218.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))